Second- and third-line therapy in gastric cancer/new options for therapy

被引：0
|
作者：
Schmalenberg, H. [1 ]
机构：
[1] Krankenhaus Dresden Friedrichstadt, Med Klin 4, Dresden, Germany
来源：
ONCOLOGY RESEARCH AND TREATMENT | 2016年 / 39卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
V435
引用
收藏
页码：128 / 128
页数：1
相关论文
共 50 条
  • [1] Safety and continuity of second- and third-line therapy with paclitaxel or irinotecan for advanced and recurrent gastric cancer
    Kimura, Michio
    Usami, Eiseki
    Kanematsu, Tetsufumi
    Iwai, Mina
    Yoshimura, Tomoaki
    Mori, Hiromi
    Sugiyama, Tadashi
    Teramachi, Hitomi
    MOLECULAR AND CLINICAL ONCOLOGY, 2014, 2 (03) : 466 - 472
  • [2] Tisotumab Vedotin as Second- or Third-Line Therapy for Recurrent Cervical Cancer
    Vergote, Ignace
    Gonzalez-Martin, Antonio
    Fujiwara, Keiichi
    Kalbacher, Elsa
    Bagameri, Andrea
    Ghamande, Sharad
    Lee, Jung-Yun
    Banerjee, Susana
    Maluf, Fernando Cotait
    Lorusso, Domenica
    Yonemori, Kan
    Van Nieuwenhuysen, Els
    Manso, Luis
    Woelber, Linn
    Westermann, Anneke
    Covens, Allan
    Hasegawa, Kosei
    Kim, Byoung-Gie
    Raimondo, Miriam
    Bjurberg, Maria
    Cruz, Felipe Melo
    Angelergues, Antoine
    Cibula, David
    Barraclough, Lisa
    Oaknin, Ana
    Gennigens, Christine
    Nicacio, Leo
    Teng, Melinda Siew Leng
    Whalley, Elizabeth
    Soumaoro, Ibrahima
    Slomovitz, Brian M.
    NEW ENGLAND JOURNAL OF MEDICINE, 2024, 391 (01): : 44 - 55
  • [3] Cost-effectiveness of tisotumab vedotin as a second- or third-line therapy for cervical cancer
    Huo, Gengwei
    Liu, Wenjie
    Chen, Peng
    JOURNAL OF GYNECOLOGIC ONCOLOGY, 2024, 35 (05)
  • [4] Vinorelbine and gemcitabine as second- or third-line therapy for malignant pleural mesothelioma
    Zauderer, Marjorie G.
    Kass, Samantha L.
    Woo, Kaitlin
    Sima, Camelia S.
    Ginsberg, Michelle S.
    Krug, Lee M.
    LUNG CANCER, 2014, 84 (03) : 271 - 274
  • [5] Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature
    ter Veer, Emil
    Mohammad, Nadia Haj
    van Valkenhoef, Gert
    Ngai, Lok Lam
    Mali, Rosa M. A.
    van Oijen, Martijn G. H.
    van Laarhoven, Hanneke W. M.
    CANCER AND METASTASIS REVIEWS, 2016, 35 (03) : 439 - 456
  • [6] Second- and third-line systemic therapy in patients with advanced esophagogastric cancer: a systematic review of the literature
    Emil ter Veer
    Nadia Haj Mohammad
    Gert van Valkenhoef
    Lok Lam Ngai
    Rosa M. A. Mali
    Martijn G. H. van Oijen
    Hanneke W. M. van Laarhoven
    Cancer and Metastasis Reviews, 2016, 35 : 439 - 456
  • [7] Second- or third-line chemotherapy in NSCLC
    Sorensen, JB
    LUNG CANCER, 2004, 45 : S18 - S18
  • [8] A phase II study of ganetespib (G) as second- or third-line therapy for metastatic pancreatic cancer (MPC).
    Thota, Ramya
    Goff, Laura Williams
    Chan, Emily
    Berlin, Jordan
    Jones, C. Michael
    McClanahan, Pamela
    Ayers, Gregory Dan
    Cardin, Dana Backlund
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [9] UPADACITINIB AS SECOND- AND THIRD-LINE SALVAGE THERAPY FOR REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS
    Hassan, Syed Adeel
    Perry, Courtney
    Flomenhoft, Deborah
    Richardson, Brooks
    Kapur, Neeraj
    Berinstein, Jeffrey
    Barrett, Terrence
    GASTROENTEROLOGY, 2024, 166 (03) : S124 - S125
  • [10] UPADACITINIB AS SECOND- AND THIRD-LINE SALVAGE THERAPY FOR REFRACTORY ACUTE SEVERE ULCERATIVE COLITIS
    Hassan, Syed Adeel
    Perry, Courtney
    Flomenhoft, Deborah
    Richardson, Brooks
    Kapur, Neeraj
    Berinstein, Jeffrey
    Barrett, Terrence
    INFLAMMATORY BOWEL DISEASES, 2024, 30
12345